{"id":20074,"date":"2024-09-03T22:01:44","date_gmt":"2024-09-03T22:01:44","guid":{"rendered":"https:\/\/beyondtype2.org\/resources\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/"},"modified":"2024-12-09T18:47:33","modified_gmt":"2024-12-09T18:47:33","slug":"fda-embecta-sistema-administracion-insulina-dt1-dt2","status":"publish","type":"resources","link":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/","title":{"rendered":"La FDA aprob\u00f3 el nuevo sistema de administraci\u00f3n de insulina de Embecta para la diabetes tipo 1 y 2"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">En un avance significativo para el cuidado de la diabetes, <\/span><a href=\"https:\/\/www.embecta.com\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Embecta Corp<\/span><\/a><span style=\"font-weight: 400;\">. ha recibido la autorizaci&oacute;n 510(k) de la Administraci&oacute;n de Alimentos y Medicamentos de EE. UU. (<\/span><i><span style=\"font-weight: 400;\">FDA, por sus siglas en ingl&eacute;s<\/span><\/i><span style=\"font-weight: 400;\">) por su innovador sistema desechable de administraci&oacute;n de insulina dise&ntilde;ado para adultos con diabetes tanto <\/span><a href=\"https:\/\/beyondtype1.org\/es\/diabetes-tipo-1\/\"><span style=\"font-weight: 400;\">tipo 1<\/span><\/a><span style=\"font-weight: 400;\"> como <\/span><a href=\"https:\/\/beyondtype1.org\/es\/la-diabetes-tipo-2\/\"><span style=\"font-weight: 400;\">tipo 2<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Este innovador sistema cuenta con una microinfusora de parche sin c&aacute;mara con un dep&oacute;sito de insulina de 300 unidades, lo que lo hace especialmente adecuado para personas con diabetes tipo 2 que requieren dosis diarias m&aacute;s altas de <\/span><a href=\"https:\/\/beyondtype1.org\/es\/todo-sobre-la-insulina\/\"><span style=\"font-weight: 400;\">insulina<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">El nuevo sistema aborda una brecha importante en las herramientas de manejo de la diabetes. Aunque nueve de cada 10 personas con diabetes tienen diabetes tipo 2, la mayor&iacute;a de las soluciones de administraci&oacute;n automatizada de insulina existentes est&aacute;n dise&ntilde;adas principalmente para la diabetes tipo 1.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">La nueva microinfusora de parche de Embecta cumple con esta necesidad insatisfecha con una mayor capacidad de insulina, ofreciendo una opci&oacute;n m&aacute;s conveniente para quienes pasan de inyecciones diarias m&uacute;ltiples a la terapia con microinfusora.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Un estudio reciente demostr&oacute; que este dep&oacute;sito de 300 unidades podr&iacute;a satisfacer el requerimiento de insulina del 64 % de los adultos con diabetes tipo 2 durante un periodo de uso de tres d&iacute;as, en comparaci&oacute;n con solo el 38 % con un dep&oacute;sito de 200 unidades.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">La microinfusora de parche totalmente desechable proporciona administraci&oacute;n de insulina basal y en bolo ajustable durante hasta tres d&iacute;as, lo que ofrece flexibilidad y facilidad de uso. El control bloqueado con tecnolog&iacute;a inal&aacute;mbrica Bluetooth&reg; y una pantalla t&aacute;ctil a color que la acompa&ntilde;a mejoran a&uacute;n m&aacute;s la experiencia del usuario, simplificando el manejo de la diabetes.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Embecta piensa desarrollar un <\/span><a href=\"https:\/\/beyondtype1.org\/es\/la-guia-para-crear-tu-propio-circuito-cerrado-diy-looping\/\"><span style=\"font-weight: 400;\">sistema de circuito cerrado<\/span><\/a><span style=\"font-weight: 400;\"> que incluye un algoritmo de dosificaci&oacute;n de insulina con el objetivo de presentarlo en el futuro a la FDA para ampliar a&uacute;n m&aacute;s su oferta de productos.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Para ver m&aacute;s detalles, <\/span><a href=\"https:\/\/www.embecta.com\/en-us\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">visita embecta.com<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p>&nbsp;<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>En un avance significativo para el cuidado de la diabetes, Embecta Corp. ha recibido la autorizaci&oacute;n 510(k) de la Administraci&oacute;n de Alimentos y Medicamentos de EE. UU. (FDA, por sus siglas en ingl&eacute;s) por su innovador sistema desechable de administraci&oacute;n de insulina dise&ntilde;ado para adultos con diabetes tanto tipo 1 como tipo 2. Este innovador [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":20076,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-20074","resources","type-resources","status-publish","has-post-thumbnail","hentry","diabetes-types-tipo-1","diabetes-types-tipo-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La FDA aprob\u00f3 el nuevo sistema de administraci\u00f3n de insulina de Embecta para la diabetes tipo 1 y 2 | Beyond Type 1<\/title>\n<meta name=\"description\" content=\"La FDA aprueba el nuevo sistema de administraci\u00f3n de insulina de Embecta, una bomba de parche sin tubo con un dep\u00f3sito de 300 unidades, ideal para la diabetes tipo 1 y tipo 2.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA aprob\u00f3 el nuevo sistema de administraci\u00f3n de insulina de Embecta para la diabetes tipo 1 y 2 | Beyond Type 1\" \/>\n<meta property=\"og:description\" content=\"La FDA aprueba el nuevo sistema de administraci\u00f3n de insulina de Embecta, una bomba de parche sin tubo con un dep\u00f3sito de 300 unidades, ideal para la diabetes tipo 1 y tipo 2.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/\" \/>\n<meta property=\"og:site_name\" content=\"Beyond Type 1\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/beyondtype1\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-09T18:47:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-EMBECTA-FDA-NEWS-HEADER-2024.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"733\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@BeyondType1\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/fda-embecta-sistema-administracion-insulina-dt1-dt2\\\/\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/fda-embecta-sistema-administracion-insulina-dt1-dt2\\\/\",\"name\":\"La FDA aprob\u00f3 el nuevo sistema de administraci\u00f3n de insulina de Embecta para la diabetes tipo 1 y 2 | Beyond Type 1\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/fda-embecta-sistema-administracion-insulina-dt1-dt2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/fda-embecta-sistema-administracion-insulina-dt1-dt2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BT1-EMBECTA-FDA-NEWS-HEADER-2024.png\",\"datePublished\":\"2024-09-03T22:01:44+00:00\",\"dateModified\":\"2024-12-09T18:47:33+00:00\",\"description\":\"La FDA aprueba el nuevo sistema de administraci\u00f3n de insulina de Embecta, una bomba de parche sin tubo con un dep\u00f3sito de 300 unidades, ideal para la diabetes tipo 1 y tipo 2.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/fda-embecta-sistema-administracion-insulina-dt1-dt2\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/beyondtype1.org\\\/es\\\/fda-embecta-sistema-administracion-insulina-dt1-dt2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/fda-embecta-sistema-administracion-insulina-dt1-dt2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BT1-EMBECTA-FDA-NEWS-HEADER-2024.png\",\"contentUrl\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BT1-EMBECTA-FDA-NEWS-HEADER-2024.png\",\"width\":2048,\"height\":733},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/fda-embecta-sistema-administracion-insulina-dt1-dt2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA aprob\u00f3 el nuevo sistema de administraci\u00f3n de insulina de Embecta para la diabetes tipo 1 y 2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/\",\"name\":\"Beyond Type 1\",\"description\":\"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.\",\"publisher\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#organization\",\"name\":\"Beyond Type 1\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/header-logo.svg\",\"contentUrl\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/header-logo.svg\",\"width\":56,\"height\":56,\"caption\":\"Beyond Type 1\"},\"image\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/beyondtype1\",\"https:\\\/\\\/x.com\\\/BeyondType1\",\"http:\\\/\\\/instagram.com\\\/BeyondType1\\\/\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/BeyondType1\",\"https:\\\/\\\/www.tiktok.com\\\/@beyondtype1\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/beyond-type1\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA aprob\u00f3 el nuevo sistema de administraci\u00f3n de insulina de Embecta para la diabetes tipo 1 y 2 | Beyond Type 1","description":"La FDA aprueba el nuevo sistema de administraci\u00f3n de insulina de Embecta, una bomba de parche sin tubo con un dep\u00f3sito de 300 unidades, ideal para la diabetes tipo 1 y tipo 2.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/","og_locale":"es_ES","og_type":"article","og_title":"La FDA aprob\u00f3 el nuevo sistema de administraci\u00f3n de insulina de Embecta para la diabetes tipo 1 y 2 | Beyond Type 1","og_description":"La FDA aprueba el nuevo sistema de administraci\u00f3n de insulina de Embecta, una bomba de parche sin tubo con un dep\u00f3sito de 300 unidades, ideal para la diabetes tipo 1 y tipo 2.","og_url":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/","og_site_name":"Beyond Type 1","article_publisher":"https:\/\/www.facebook.com\/beyondtype1","article_modified_time":"2024-12-09T18:47:33+00:00","og_image":[{"width":2048,"height":733,"url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-EMBECTA-FDA-NEWS-HEADER-2024.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@BeyondType1","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/","url":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/","name":"La FDA aprob\u00f3 el nuevo sistema de administraci\u00f3n de insulina de Embecta para la diabetes tipo 1 y 2 | Beyond Type 1","isPartOf":{"@id":"https:\/\/beyondtype1.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/#primaryimage"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/#primaryimage"},"thumbnailUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-EMBECTA-FDA-NEWS-HEADER-2024.png","datePublished":"2024-09-03T22:01:44+00:00","dateModified":"2024-12-09T18:47:33+00:00","description":"La FDA aprueba el nuevo sistema de administraci\u00f3n de insulina de Embecta, una bomba de parche sin tubo con un dep\u00f3sito de 300 unidades, ideal para la diabetes tipo 1 y tipo 2.","breadcrumb":{"@id":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/#primaryimage","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-EMBECTA-FDA-NEWS-HEADER-2024.png","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-EMBECTA-FDA-NEWS-HEADER-2024.png","width":2048,"height":733},{"@type":"BreadcrumbList","@id":"https:\/\/beyondtype1.org\/es\/fda-embecta-sistema-administracion-insulina-dt1-dt2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/beyondtype1.org\/es\/"},{"@type":"ListItem","position":2,"name":"La FDA aprob\u00f3 el nuevo sistema de administraci\u00f3n de insulina de Embecta para la diabetes tipo 1 y 2"}]},{"@type":"WebSite","@id":"https:\/\/beyondtype1.org\/es\/#website","url":"https:\/\/beyondtype1.org\/es\/","name":"Beyond Type 1","description":"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.","publisher":{"@id":"https:\/\/beyondtype1.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/beyondtype1.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/beyondtype1.org\/es\/#organization","name":"Beyond Type 1","url":"https:\/\/beyondtype1.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","width":56,"height":56,"caption":"Beyond Type 1"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/beyondtype1","https:\/\/x.com\/BeyondType1","http:\/\/instagram.com\/BeyondType1\/","https:\/\/www.youtube.com\/c\/BeyondType1","https:\/\/www.tiktok.com\/@beyondtype1","https:\/\/www.linkedin.com\/company\/beyond-type1\/"]}]}},"_links":{"self":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/20074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/types\/resources"}],"author":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/comments?post=20074"}],"version-history":[{"count":0,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/20074\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media\/20076"}],"wp:attachment":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media?parent=20074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}